PureTech Health plc is reaping the benefits of the excitement surrounding the schizophrenia candidate KarXT from Karuna Therapeutics, Inc., one of the companies it founded, with the sale of royalty rights that could bring in up to $500m to advance its own pipeline.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?